Connect with us

Cannabis News

Anti-Marijuana Groups And Pharma Company Ask Court To Revive Lawsuit Challenging Medicare Hemp Coverage Program

Published

on

A coalition of anti-marijuana groups and a cannabis-focused biopharmaceutical corporation are asking a federal appeals court to overturn a lawsuit challenging a new Trump administration initiative. Cover up to $500 of hemp-derived products annually for eligible Medicare patients.

Last month, Judge Trevor N. McFadden The Centers for Medicare and Medicaid Services (CMS) rejected the challenge to the program implemented It focuses largely on CBD, but also allows a certain amount of THC in its products.

He ruled that prohibitionist groups and activists, led by Smart Approaches to Marijuana (SAM), as well as MMJ International Holdings and its subsidiary, a cannabis-based biopharmaceutical corporation, “have no standing to bring this case.”

The plaintiffs now appeal to the US Court of Appeals for the District of Columbia Circuit.

“Notice is hereby given that Plaintiffs Intelligent Approaches to Marijuana, Cannabis Industry Victim Education Litigants, Hillsborough County Anti-Drug Alliance, MMJ International Holdings, Inc., MMJ Biopharma Cultivation, Inc. and MMJ Biopharma Labs, Inc. are filing an appeal in the United States Circuit Court of Appeals for May 22, 2026 in favor of Plaintiffs,” reads the brief filed Friday.

SAM CEO Kevin Sabet said in a press release, “This fight is far from over, and we will not stand idly by as long as CMS allows non-FDA-approved products to be given to seniors.”

“This program puts CMS in bed with Big Tobacco and Big Weed, and puts older Americans at risk,” he argued. “CMS is mandated to promote public health, and this program would degrade it. Not only would this move put the elderly at risk, it would also send the wrong message to the American public about the safety of these products, which have been found to have numerous negative side effects.”

In April, lawyers Section of Health and Human Services. Robert F. Kennedy Jr. and CMS Director Mehmet Oz presented the summary arguing that Anti-cannabis organizations filed lawsuit against Medicare hemp coverage policy they have no value to bring the case.

Outside of the CMS hemp program challenge, SAM and MMJ were presented separately The lawsuits challenge the Trump administration’s move to federally regulate marijuana.

Beyond advocacy organizations and MMJ, the CMS hemp case involves individual plaintiffs, including anti-marijuana attorney David Evans, who says he had a Substance Access Beneficiary Engagement Incentive (BEI) lawsuit as a Medicare recipient.

McFadden previously denied the plaintiffs’ request for a temporary restraining order to stop the program from running on April 1st.

Notably, the government’s motion to dismiss the case says it was prepared in part by Matthew Zorn, an HHS attorney, before he took the federal job. litigated numerous cases against government agencies on behalf of plaintiffs seeking marijuana and drug policy reform..

The CMS initiative comes after President Donald Trump signed an executive order in December calling on the attorney general to finalize a federal marijuana redistricting rule, now underway, that also includes “access improvement” components for full-spectrum CBD products.

Under the program, inhalable preparations are not allowed, and products cannot contain more than 0.3 percent delta-9 THC by dry weight and a total of 3 milligrams of THC per serving.

The THC limit could potentially change if the law the president signed late last year goes into effect as planned in November. Such a policy would strictly limit the types of cannabis products currently allowed under the 2018 Farm Bill signed by Trump during his first term, specifically banning hemp derivatives with a total of 0.4 milligrams of THC per container.

This week, the White House asked Congress to take action amend the proposed ban to maintain legal access to hemp-derived full-spectrum CBD products.

In a summary of the CMS hemp case, the federal agency stated that “CMS does not pay for hemp products under the BEI.”

“Participating providers supply eligible products at their own cost, subject to an annual limit of $500 per beneficiary. BEI operates within a shared savings framework that defines the underlying model. If a provider’s investment in beneficiary engagement reduces the beneficiary’s total cost of care, it shares in the savings generated by the provider and CMS. If it does not absorb new, if the provider does not absorb new. BEI is essentially entitled to certain interventions. It is a provider decision that allows one to reduce downstream claims.

Meanwhile, the White House Office of Management and Budget recently held a series of meetings a Food and Drug Administration (FDA) CBD product enforcement policy.

The FDA also issued guidance making it clear that it does not intend to interfere Establish a Medicare coverage plan for hemp-derived products.

CMS finalized a rule that will be adopted separately Coverage of certain hemp products, primarily as specialized health-related benefits, through Medicare Advantage the plans

read it filing appeal the dismissal of the lawsuit challenging the Medicare hemp program below:

user photo Nanny Kimzy.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Redefining the standards of UK cannabis

Published

on

By

Dalgety Ltd has entered into a partnership with Curaleaf Laboratories to supply pharmaceutical grade cannabis medicines to the UK cannabis market. The arrangement combines Dalgety’s cultivation operations, which are certified to EU-GMP standards, with Curaleaf Laboratories’ pharmaceutical manufacturing and distribution capabilities. According to the companies, this creates a UK-based supply route that does not rely on imported cannabis flowers, as Dalgety cultivates its product in-house. Dalgety claims it was the first company in the UK to grow, manufacture and supply EU-GMP medical cannabis from a single site.

© Curaleaf Laboratories

The growing facility, which is more than 30,000 square feet, is located indoors and uses hydroponic growing methods along with automated lighting, irrigation, humidity and temperature control systems. The company reports that it uses AI-assisted environmental monitoring, which extends the traceability of batches to the final product and compares them to operating standards for air filtration systems. Post-harvest processing is said to follow EU-GMP protocols, including microbial and cannabinoid testing.

The stated goal of this approach is to reduce between-harvest variation in terms of THC and CBD content, terpene profiles, and microbial safety. Dalgety says his cultivation is overseen by staff with experience in horticulture and biochemistry, some of whom have worked on cannabis cultivation projects internationally.

Through a partnership with Curaleaf Laboratories, Dalgety’s UK-grown cannabis is processed and distributed through a UK-based supply chain, rather than imported from overseas. Companies suggest that this arrangement can shorten the time it takes to get products to market compared to importing, and reduce the likelihood of supply disruptions. Because Dalgety and Curaleaf Laboratories are involved in cultivation, manufacturing and distribution, the companies say this oversees the product at every stage, making it clearer for prescribers to see where and how the product was made.

© Curaleaf Laboratories

Dalgety operates to EU-GMP standards and has been subject to regulatory review by the MHRA and the Home Office. Its operations include environmental monitoring, microbial testing, stability testing, controlled drying and curing procedures and quality assurance processes, along with controlled and secure facilities.

The company describes its work as controlled environment farming, hydroponic systems, environmental control technology, and efforts to stabilize cannabis genetics and phenotypes for batch-to-batch consistency.

© Curaleaf Laboratories

Dalgety has also opened its cultivation facilities for visits to healthcare professionals, clinicians, pharmacists, researchers and other industry stakeholders. The company says this is in response to the fact that much of the cannabis historically supplied to UK patients has been grown overseas, which has limited opportunities for UK clinicians to see first-hand the cultivation and quality control processes. These tours aim to provide visitors with information on cultivation standards, EU-GMP compliance procedures, environmental control systems, testing processes and the regulatory framework governing cannabis manufacturing in the UK.

Dalgety and Curaleaf Laboratories describe their partnership as expanding access to UK-grown medical cannabis, improving supply chain reliability and helping to meet sector regulations, placing it in the wider context of growing demand for cannabis-based treatments from UK patients.

For more information:
Curaleaf Laboratories
Email: (email protected)
https://curaleaflaboratories.co.uk/

Continue Reading

Cannabis News

Arkansas GOP Governor And Democratic Challenger Agree On Opposing Marijuana Legalization

Published

on

By

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans.”

Antoinette Grajeda, Arkansas attorney

Contains medical marijuana It generated more than $1 billion since Arkansas voters legalized it in 2016

After the state opened its first dispensary in 2019, thousands of Arkansans joined the program and spent a record $291.1 million on medical marijuana in 2025, according to the state Department of Finance and Administration.

Tax revenue from those sales now supports free breakfast for public school students after lawmakers passed legislation last year.

Medical marijuana programs have expanded across the country, as has recreational marijuana. Two dozen states, including neighboring Missouri, allow recreational marijuana use, according to state legislatures.

Arkansas voters rejected an effort to legalize recreational marijuana in 2022despite the national teams spending millions in support of the measure.

Restrictions on marijuana have been relaxed at the federal level, and the US Department of Justice earlier this year downgraded the drug classification of medicinal cannabis.

Here’s what Arkansas’ gubernatorial candidates — Democratic State Sen. Fred Love, Republican Gov. Sarah Huckabee Sanders and Libertarian Colt Shelby — have to say about legalizing recreational marijuana.

Democratic State Sen. Fred Love

Love said he opposes legalization during a debate at the Arkansas Press Association’s annual conference in June.

Sitting in a crosswalk at her daughter’s school, Love said “marijuana is all over” as the children exited their vehicles. When you grow up in a community where recreational marijuana is present, you see that it doesn’t always have a positive effect, he said.

“I don’t think it’s something I support,” Love said. “I’ve seen the long-term impact.”

While he doesn’t personally support it, Love said he would support legalizing recreational marijuana if Arkansans voted on it.

Libertarian Colt Shelby

Shelby said he’s for whatever Arkansans want, so he would support legalizing recreational marijuana if voters approve.

Shelby said the state’s elected officials have forgotten what matters most is what Arkansans want, which is why she’s running for office.

Although Shelby says she doesn’t smoke weed herself, she says almost everyone knows it and she has the meds.

“It brings a lot of good things, so I won’t say that I’m against it, but let the people decide”, he said in the debate in June.

Republican Governor Sarah Huckabee Sanders

Sanders did not participate in the June debate, but said in an emailed statement that he does not support the legalization of recreational marijuana.

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans,” Sanders said.

Sanders vetoed a law passed by the Legislature last year dispensaries have been allowed to deliver orders via a delivery vehicle or drive-through window.

The governor signed into law in 2023 the bill protecting the rights for medical marijuana patients and caregivers to obtain a license to carry a concealed handgun.

In 2025, Sanders backed that uses medical marijuana revenue to support free breakfast for all public school students.

This story was first published by the Arkansas Advocate.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Will the top World Cup expert in the fruit, vegetable, and horticulture sector come from Canada, the U.S. or Belgium?

Published

on

By






FreshPublishers 2026 World Cup Group Stage






The World Cup is coming to an end, with the third-place play-off between France and England on Saturday, and the final between Spain and Argentina the following day. It won’t be long until the grand winner of FreshPublishers’ first World Cup pool is revealed.

© Fresh Publishers

As previously reported, Slim Kooli from Courchesne Laros is the favorite to win the €1,000 prize. He has secured a comfortable lead over Nol Batist of North American Interstate Greenhouse Company, while buyer Bjorn Van Ryckeghem of Deprez Construct is currently in third place.

1 Sim School Spain 1–0 2–1 737 9716
2 Nol Batist France 2–1 1–1 674 9433
3 Bjorn Van Ryckeghem France 2–2 3–1 674 9264
4 Christian Anton Smedshaug England 1–2 1–2 659 9134
5 Perry Springintveld Spain 1–1 2–1 647 9105
6 Willem Tijssen Spain 2–0 2–1 710 9098
7 Hans Borsboom Spain 2–1 2–1 528 9058
8 Bart Triemstra Spain 2–1 2–1 737 9052
9 Youness Bensaid Spain 2–1 1–1 722 8954
10 Vijay Dijkstra Portugal 2–0 2–1 382 8953

However, there have been some surprises during the tournament, and bonus points must be added, so we will keep the suspense a little longer. On Monday we will find out who is the main World Cup announcer in the international fruit, vegetable and horticulture sector…



Publication date:













Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media